Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telotristat Ethyl Plus Chemotherapy in Advanced Biliary Tract Cancer
NCT03790111Phase 2Terminated
- Sponsor
- TerSera Therapeutics
- Start
- Mar 2019
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telotristat ethyl in biliary tract cancer (BTC), sponsored by TerSera Therapeutics. Primary endpoints: Progression-Free Survival at Month 6 and Project Overall Survival Rate at Month 6. Started Mar 2019; status: terminated.
02
Drugs
telotristat ethyl
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03790111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790111.